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Abstract
Side population (SP) and ABC transporter expression enrich for stem cells in numerous tissues. We explored if this
phenotype characterised human bladder cancer stem cells (CSCs) and attempted to identify regulatory mechanisms.
Focusing on non-muscle invasive bladder cancer (NMIBC), multiple human cell lines were used to characterise SP and ABC
transporter expression. In vitro and in vivo phenotypic and functional assessments of CSC behaviour were undertaken.
Expression of putative CSC marker ABCG2 was assessed in clinical NMIBC samples (n = 148), and a role for MAPK signalling, a
central mechanism of bladder tumourigenesis, was investigated. Results showed that the ABCG2 transporter was
predominantly expressed and was up-regulated in the SP fraction by 3-fold (ABCG2hi) relative to the non-SP (NSP) fraction
(ABCG2low). ABCG2hi SP cells displayed enrichment of stem cell markers (Nanog, Notch1 and SOX2) and a three-fold increase
in colony forming efficiency (CFE) in comparison to ABCG2low NSP cells. In vivo, ABCG2hi SP cells enriched for tumour growth
compared with ABCG2low NSP cells, consistent with CSCs. pERK was constitutively active in ABCG2hi SP cells and MEK
inhibition also inhibited the ABCG2hi SP phenotype and significantly suppressed CFE. Furthermore, on examining clinical
NMIBC samples, ABCG2 expression correlated with increased recurrence and decreased progression free survival.
Additionally, pERK expression also correlated with decreased progression free survival, whilst a positive correlation was
further demonstrated between ABCG2 and pERK expression. In conclusion, we confirm ABCG2hi SP enriches for CSCs in
human NMIBC and MAPK/ERK pathway is a suitable therapeutic target.
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Introduction
Transitional cell carcinoma (TCC) of the urinary bladder has a
worldwide annual incidence of over 350,000 new cases and
145,000 deaths [1]. In the US, it is the fifth most common
malignancy accounting for over 70,000 new cases a year and an
estimated annual spend of $3.5 billion on cancer treatment [2,3].
Although 85% of patients present with less aggressive non-muscle
invasive bladder cancer (NMIBC), they have a high risk of
recurrence and those with unfavourable characteristics such as
multifocal disease, high grade tumours, with or without concom-
itant carcinoma in situ (CIS), are at particular risk of disease
progression. Intravesical Bacille Calmette-Gue´rin (BCG) can
reduce the risk of progression by 27% in patients with high risk
NMIBC [4] but those that fail to respond typically undergo
morbid surgery to remove the bladder. For patients that present
with, or progress to, muscle invasive bladder cancer (MIBC), the
chance of surviving more than 5 years following treatment is
approximately 50–60% [5,6]. This background indicates that
novel therapeutic approaches against NMIBC are urgently needed
to eradicate disease before an invasive phenotype develops [7].
Recent advances in cancer biology have included the char-
acterisation of cancer stem cells (CSCs), a small subpopulation of
tumour cells that are tumour initiating and drive the production of
the rest of the cancer. CSCs have been described in an increasing
number of tumour sites including haematopoetic, breast, colon,
melanoma and prostate [8–12]. It is becoming clear that it is
essential to target these cells as they determine response to
treatment [13]. The categorisation and selection of a side
population (SP) phenotype by flow cytometry [14] enriches for
CSCs in numerous tumours [15–18]. Recent demonstration of SP
in bladder cancer necessitates further investigation of its potential
role in characterising CSCs [19].
The pathogenesis of bladder cancer appears closely linked to
distinct molecular pathways [20,21]. Over 70% of NMIBCs
harbour activating mutations of fibroblast growth factor receptor 3
(FGFR3) leading to constitutive activation of MAPK signalling
[22,23]. Furthermore, up-regulation of EGFR/ErbB family
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receptors is associated with increasing grade and stages of bladder
cancer [24,25]. Of relevance, SP phenotype is mediated by the
ATP-binding cassette (ABC) family of transporter proteins [14],
and the breast cancer-resistant protein-1 (BCRP1)/ABCG2
transporter has been shown to be the main mediator of this
phenotype [26]. In particular, ABCG2 is in turn regulated by
MAPK [27] and a role for MAPK/ERK signalling pathway in the
regulation of SP has been suggested (Tsichuda et al 2008).
As a first step in informing the design of novel therapies for
NIMBC, we aimed to characterise CSCs in human bladder cancer
using SP selection and explore regulation through the MAPK/
ERK signalling axis.
Materials and Methods
Reagents and Cell culture
Human bladder cancer cell RT4, RT112 and J82 were
obtained from the American Type Culture Collection (ATCC)
and cultured in RPMI 1640 (Sigma) supplemented with 10% fetal
bovine serum (FBS) and 1% L-glutamine - referred to as full media
(FM). The highly metastatic human TCC cell line 253JB-V was
generously provided by Prof Colin Dinney [28] and cultured in
MEMalpha media supplemented with 5% FBS. All cells were
grown at 37uC in the presence of 5% CO2. MEK1/2 specific
inhibitor, U0126 (Cell Signalling Technology), and rEGF (Sigma)
were utilised in studies to modulate MAPK signalling. Control
cells for comparison included cultures in basal media (BM) lacking
FBS and FM.
Hoechst Dye Efflux Assay
Cells were stained with Hoechst 33342 dye using modification
of a previously described protocol [14]. Briefly, Hoechst 33342 dye
(2.5 mg/ml) was added alone or in the presence of reserpine
(50 mM), verapamil (50 mM) or fumitremorgin C (10 mM) and cells
were incubated at 37uC for 90 min and shaken every 30 min. Cell
surface marker analyses following Hoechst 33342 dye staining
were performed with anti-ABCG2-FITC (clone 5D3, Millipore)
co-labelling on ice for 20 min. Normal mouse IgG-FITC was used
as isotype control (Upstate). Propidium iodide (PI) (2 mg/ml) gated
viable cells. Analysis and sorting were carried out on a
FACSDIVA flow cytometer (Becton Dickinson).
RNA Extraction and Real-time PCR Analysis
Total RNA was extracted using the High Pure RNA kit (Roche)
and reversed transcribed using random primers (Promega) and
Superscript III reverse transcriptase enzyme (Invitrogen). Real
time PCR was carried out with SYBR Green mastermix
containing RoxTM and UDG (Invitrogen) using the ABI Prism
7900HT Sequence Detection System (Applied Biosystems). For
primer sequences see Table S1. Levels of expression were
normalised to GAPDH housekeeping gene.
Colony Forming Assay
FACS sorted cells were seeded into six-well plates at a density of
100 cells/well. After 14 days colonies were fixed with Carnoy’s
fixative and stained with 0.4% crystal violet (w/v) for colony
counting using ColCounter (Oxford Optronix), omitting ,64 cell
colonies as they represent early abortive colonies. Colony forming
efficiency (CFE, %) was calculated as [(no. colonies counted/no.
cells seeded)6 100].
Cell Cycle
FACS sorted cells were stained with DAPI for cell cycle analysis
using CyStain DNA 2step kit (Partec). Propidium iodide (2 mg/ml)
gated viable cells. To discriminate against nuclear debris and
doublets, cells were gated on FSC and SSC. Flow cytometry cell
cycle software (CellQuest Pro, BD Biosciences) was used to
calculate DNA content and calculate subG1, G1, S-phase and
G2M phase statistics.
Figure 1. Identification of SP phenotype in bladder cancer cell lines. RT112, RT4, J82 and 253JB-V cells were stained with Hoechst 33342 dye
alone or in the presence of reserpine and analysed by flow cytometry measuring Hoechst blue vs Hoechst red fluorescence. The SP was gated and
represented as a percentage of the whole viable cell population following PI exclusion (mean 6SE).
doi:10.1371/journal.pone.0050690.g001
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In vivo Tumourigenicity
Animal experiments were performed and conducted in accor-
dance to regulatory guidelines. Twenty three female athymic CD1
nude mice (Charles River, UK) were injected with RT112 SP and
NSP sorted cells into the right flank subcutaneous tissue. Tumour
growth was monitored by two dimensional measurement with
electronic callipers with tumour volume calculated using the
formula a26b/2, where a is the smallest measurement and b the
largest. The mice experiments were terminated when tumours
grew to a maximum of 750 mm3. The tumours were removed and
halved for immunohistochemical studies and real time PCR
studies.
Immunohistochemitry
Formalin fixed paraffin embedded archival material from
patients undergoing endoscopic resection of bladder tumour or
radical cystectomy was accessed for immunohistochemical studies
with appropriate informed consent and ethical regulatory approv-
al. In total, 148 NMIBC cases were stained with anti-ABCG2
(1:250; clone BXP-21, Millipore) and anti-p-ERK (1:100, E-4,
Santa Cruz Biotechnology) before incubation with secondary
biotinylated goat anti-mouse IgG antibody (DAKO). Immunore-
activity was visualised using Vectastain Avidin Biotin Complex Kit
(Vector Laboratories) and 3939-diaminobenzidetetrahydrochlor-
ide. Scoring was initially assessed by percentage and stain
intensity. However, the vast majority of cores expressed uniform
epithelial staining with a single intensity, with heterogeneous
staining present in only a few cases. In these cores, the intensity
with .50% area of staining was taken as the score. The
immunostaining was reviewed and scored independently by three
assessors that were blinded to the clinical data to give average
scores of staining intensity of absent (0), weak (1), moderate (2) or
strong (3). Xenografts were also stained with anti-Nanog (1:5000,
Cell Signalling), anti-Notch 1 (1:500, C-20, Santa Cruz Biotech-
nology) and anti-SOX2 (1:500, Millipore).
Figure 2. NMIBC SP cells show elevated ABCG2 transporter expression. Relative mRNA expression of ABCA2, ABCG2, MRP1 and P-
glycoprotein was determined in SP and NSP fractions of RT112 (A) and RT4 (B) cells using real time PCR. Data shown are the mean of three
independent experiments each performed in triplicate (mean6SE). *P,0.05 (Student’s two-tailed t-test). Inhibition studies were performed on RT112
(C) and RT4 (D) cells using ABCG2-specific inhibitor fumitremorgin C (FTC) and P-glycoprotein inhibitor verapamil.
doi:10.1371/journal.pone.0050690.g002
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Figure 3. ABCG2hi SP cells have a higher clonogenic ability in comparison to ABCG2low NSP cells. (A) FACS sorted cells were seeded in 6-
well plates at a density of 16102 cells/well and colonies were counted after 2 weeks. Colony forming efficiency (CFE) was calculated as described in
Materials and Methods. Data shown are the mean (6SE) of three independent experiments each done in triplicate. *P,0.05 (Student’s two-tailed t-
test). (B) Cell cycle profiles of RT112 ABCG2hi SP and ABCG2low NSP cells showing an increase in S-phase in the ABCG2hi SP fraction. (C) Serial selection,
sub-culture and cytometric fractioning between RT112 SP and NSP cells. SP and NSP cells sorted from RT112 were cultured for two weeks, restained
with Hoechst 33342 dye and reanalysed by flow cytometry. This process was repeated 4 times.
doi:10.1371/journal.pone.0050690.g003
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Western Blotting
Cells were lysed in SDS sample buffer (0.125 M Tris pH 6.8,
2% SDS, 10% glycerol, 10% b-mercaptoethanol and 0.01%
bromophenol blue) and analysed by SDS-PAGE on 12%
polyacrylamide gels, followed by transfer to nitrocellulose
HybondTM membrane (Fisher Scientific). Antibodies were used
at the following dilutions: anti-ERK 1:500 (K-23, Santa Cruz
Biotechnology) and anti-phospho-ERK 1:500 (E-4, Santa Cruz
Biotechnology). Horseradish peroxidase-conjugated secondary
antibodies (DAKO) were used at 1:500 and detected using the
enhanced chemiluminescence detection kit (Fisher Scientific).
Statistical Analysis
For real time PCR studies, the two-tailed paired t-test was used
to determine statistical significance at a level of P,0.05. For
immunohistochemistry, differences in the frequency and expres-
sion of ABCG2 were examined using Mann-Whitney U test to
assess correlations with pathological cancer grade and stage.
Patient survival was analysed using the Kaplan-Meier method with
log-rank testing, and multivariate analysis was performed using the
Cox proportional hazards model. Pearson’s correlation was used
to correlate ABCG2 and pERK expression. All tests were
undertaken using SPSS version 11.0 computer software (SPSS,
Figure 4. SP cells are more tumourigenic. (A) 16103 ABCG2hi SP and ABCG2low NSP sorted RT112 cells were subcutaneously injected into nude
mice and monitored for tumour growth. (B) Immunohistochemical staining of serial sections, of tumours derived from mice injected with 16103
ABCG2hi SP and residual cell pellets from mice injected with 16103 ABCG2low NSP sorted RT112 cells, with H&E and ABCG2 and at higher
magnification (20x). Markedly increased immunoreactivity for ABCG2 is seen in the ABCG2hiSP derived tumours. (C) Relative mRNA expression of
ABCG2 in tumours formed following injection of 16103 ABCG2hi SP and ABCG2low NSP sorted RT112 cells was determined using real time PCR. (D–F)
Relative mRNA expression of Nanog, Notch1 and SOX2 in tumours formed following injection of 16103 ABCG2hi SP and ABCG2low NSP sorted RT112
cells was determined using real time PCR. (G) Immunohistochemical staining of serial sections, of tumours formed following injection of 16103
ABCG2hi SP and ABCG2low NSP sorted RT112 cells, with Nanog, Notch1 and SOX2.
doi:10.1371/journal.pone.0050690.g004
Table 1. Tumourigenesis of ABCG2hiSP and ABCG2lowNSP
cells in nude mice at 30 days.
Cell Number Injected ABCG2hiSP ABCG2lowNSP
100,000 3/3 –
10,000 5/5 5/5
1,000 5/5 0/5
doi:10.1371/journal.pone.0050690.t001
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Inc.). All tests were two-sided and a P value of ,0.05 was taken to
indicate statistical significance.
Results
SP Cells and ABC Transporter Expression can be
Identified in Human Bladder Cancer Cells
We investigated the presence of SP in two NMIBC cell lines
(RT112 and RT4) and two MIBC cell lines (J82 and 253JB-V).
Following staining with Hoechst 33342, a SP was identified in all
four cell lines as a distinct tail extending from the main population
with the characteristic low fluorescent profile in dual wavelength
analysis (Figure 1). The gating strategy undertaken was followed as
described by Golebiewska et. al. [29] (Figure S1). Appropriate
discrimination of single and viable cells is crucial for adequate SP
characterisation. The median (6SE) proportion of each total cell
population accounted for by the SP was 12.8% (61.2%) in
RT112, 15.3% (61.1%) in RT4, 2.7% (60.9%) in J82, and 1.0%
(60.5%) in 253JB-V. The pan-ABC transporter inhibitor reser-
pine verified SP phenotype by blocking Hoechst efflux and
inhibiting low red/blue staining phenotype that characterises SP
cells.
We assessed ABC transporter expression patterns of bladder
cancer cell lines using real time PCR. Heterogeneous expressions
of multiple multidrug resistant genes were demonstrated in the
MIBC cell lines J82 and 253JB-V. However, in the NMIBC cell
lines RT4 and RT112 higher expressions of ABCG2 were seen
(Figure S2).
ABCG2 is Significantly Enriched within NMIBC SP Cells
and Maintains this Phenotype
We next focused on NMIBC disease and examined the relative
mRNA expression of four ABC transporters (ABCA2, ABCG2,
MRP1 and P-glycoprotein) in RT112 and RT4 SP and NSP
fractions using real time PCR (Figure 2A and 2B).The results
demonstrated that, in addition to ABCG2 being the major ABC
transporter in NMIBC, its expression was higher in SP cells
compared to NSP cells. The key role of ABCG2 in generating the
SP phenotype was confirmed by complete loss of SP population
following treatment with the ABCG2-specific inhibitor fumitre-
morgin C (FTC) compared to the lack of effect of treatment with
the P-glycoprotein inhibitor verapamil (Figure 2C and 2D). In
contrast, P-glycoprotein was the most differentially expressed and
functionally relevant ABC transporter in the MIBC cell line J82
(Figure S3). Furthermore, we confirmed that in NMIBC cells the
SP fraction was associated with only highest levels of ABCG2
(ABCG2hi) expression (Figure S4).
SP Cells Enrich for Stem Cell Function in vitro
We next compared the clonogenic potential of RT112
ABCG2hi SP and ABCG2low NSP cells. ABCG2hi SP cells
displayed a three-fold increase in mean (6SE) colony forming
enrichment to 56.7% (61.6%) from 18.2% (60.2%) in ABCG2low
NSP cells (Figure 3A). Similar increase in ABCG2hi SP
clonogenicity compared with ABCG2low NSP cells was demon-
strated in the additional NMIBC cell line RT4 (Figure S5).
Following the gating of non-viable cells using propidium iodide,
cell cycle analysis revealed that a greater proportion of ABCG2hi
SP cells were in S-phase in comparison to ABCG2low NSP cells,
with mean (6SE) values of 19% (65%) versus 5.5% (61) for S-
Figure 5. Inhibition of ERK signalling attenuates the fraction of ABCG2hi SP RT112 cells. (A) Western blot analysis was performed with
phospho-ERK1/2 and ERK1/2 antibodies. (B) RT112 cells were placed in FM alone or in the presence of U0126 (10 mM) for 30 min prior to staining with
Hoechst 33342. The effect of U0126 on the ‘tail’ and ‘top’ end compartments of ABCG2hiSP+ was investigated. (C) CFE of ABCG2hi SP cells with
increasing concentrations of UO126 and different sized colonies ($1 mm, $2 mm and $3 mm in diameter).
doi:10.1371/journal.pone.0050690.g005
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phase and 68% (68%) versus 94% (61%) for G1-phase,
respectively (Figure 3B).
To consider the ability of ABCG2hi SP cells to repopulate the
original phenotypic spectrum of the parent RT112 cell line, we
performed serial cultures and selections of SP and NSP fractions
before re-staining with Hoechst 33342 and reanalysing by flow
cytometry (Figure 3C). The results showed that following the first
round of selection, culture and flow cytometry, cultures derived
from both SP and NSP cells each gave rise again to a similar
distribution of SP and NSP cells. If this process was then continued
with repeated cycles of selection, separate culture and flow
cytometric sorting, the proportion of cells from SP sub-cultures
that were located in the SP fraction increased with each round,
whilst there was a marked decrease in the SP fraction of cells
derived from NSP sub-cultures.
Figure 6. Immunohistochemical expression of ABCG2 in clinical bladder cancer. (A) ABCG2 expression in normal urothelium, low grade
(LG) and high grade (HG) NMIBC is typically non-specific and can be seen nuclear and cytoplasmic. (B) Correlation of ABCG2 immunostaining intensity
with grade and stage in NMIBC. (C) Kaplan-Meier curves illustrating outcomes of ABCG2 intensity (0, 1, 2 and 3) with recurrence and progression free
survival (p,0.001, Log Rank analyses). (D) Kaplan-Meier curves illustrating outcomes of pERK intensity (0, 1, 2 and 3) with progression free survival
(p,0.001, Log Rank analyses). (E) Correlation of ABCG2 and pERK expression (p = 0.005, Pearson’s r = 0.99).
doi:10.1371/journal.pone.0050690.g006
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We assessed stem cell marker expression in RT112 ABCG2hi SP
and ABCG2low NSP cells by real time PCR (Figure S6A).
ABCG2hi SP cells showed increased expression of Nanog, Notch1
and SOX2 compared to ABCG2low NSP cells. Additionally,
expression of bladder basal cell markers, including CK14, CD44,
CD49f (a6 integrin) and CD104 (b4 integrin) also associated with
enrichment of CSCs, was investigated (Figure S6B). All basal cell
markers were expressed in ABCG2hi SP cells but similar levels of
expression were also seen in ABCG2low NSP cells.
SP Cells Enrich for Greater Tumour Initiating Ability
in vivo
To investigate the comparative ability of ABCG2hi SP and
ABCG2low NSP cells to form viable tumours in vivo, sorted cells
from each sub-population were separately injected subcutaneously
into CD1 nude mice and the implant sites monitored for growth.
Rapid tumour growth was observed in 5 of 5, 5 of 5, and 3 of 3
animals following implantation of 103, 104, and 105 ABCG2hi SP
cells respectively. However, ABCG2lowNSP tumour growth was
exhausted by dilution of seeding numbers to 103 cells whilst 5 of 5
mice engrafted with 103 ABCCG2hi SP cells grew tumours
(Table 1). Examining median tumour volume over time revealed
exponential growth within the ABCG2hi SP cell inoculum group
in contrast to those receiving ABCG2low NSP cells (Figure 4A).
Immunohistochemical analysis of ABCG2 expression in tu-
mours, formed following the injection of 16103 ABCG2hi SP cells
in comparison to the residual cell pellets (which were not
associated with any active growth) harvested from mice injected
with ABCG2low NSP sorted RT112 cells, showed increased
expression in ABCG2hiSP compared with ABCG2lowNSP derived
tumours (Figure 4B).
We subsequently demonstrated increased expression of ABCG2
(Figure 4C) and recognised embryonic/pluripotent stem cell
markers Nanog, Notch1 and SOX2 (Figure 4D–F), which have
been associated with tumorigenesis [30], using real time PCR in
the tumours formed following the injection of ABCG2hi SP cells
compared with the residual cell pellets harvested from mice
injected with ABCG2low NSP cells. These in vivo results were
consistent with those obtained with the parent in vitro cultured cells
(Figure S6A) with high expression of stem cell markers maintained
in tumours originating from ABCG2hi SP cells contrasting with
low expression in residual ABCG2low NSP. Of note, the selection
of tumour initiating cells by this in vivo assay resulted in enrichment
of these stem cell markers, over baseline levels in vitro, where
differences were 11-fold, 80-fold, 44-fold and 140-fold for ABCG2,
Nanog, Notch1 and SOX2 expression, respectively (p,0.05).
Furthermore, increased Nanog, Notch1 and SOX2 expression by
the ABCG2hi SP mouse xenografts was also observed by
immunohistochemical analysis (Figure 4G).
Inhibition of ERK Signalling Attenuates the SP Cancer
Stem Cell Function
We investigated the potential role of MAPK in the regulation of
the SP phenotype in NMIBC RT112 cells. Expression of ERK,
JNK and p38 as well as the PI3K/Akt and STAT signalling
pathways was determined by real time PCR (Figure S7A). EGFR,
ERK1 and ERK2 expression by both ABCG2hi SP and
ABCG2low NSP cells was documented at much higher levels than
the other signalling components, suggesting that these enzymes
were likely to play a significant role in the MAPK signalling in
RT112 cells. Enzymatic activation was subsequently explored and
pERK was confirmed to be constitutively expressed at a higher
level in ABCG2hi SP cells (Figure 5A). Furthermore, elevated
pERK expression was also seen in the ABCG2hi SP xenografts
(Figure S7B). To further test the relevance of the MAPK/ERK
pathway as a potential target in RT112 ABCG2hi SP, the
functional effects of U0126, a specific inhibitor for MEK1 and
MEK2, were assessed. Cells pre-treated with U0126 for 30, 60 or
120 minutes had no detectable phosphorylated ERK expression,
thus confirming the inhibition of ERK activation even in the
presence of EGF stimulation (Figure S7C). Additionally, there was
no significant change in PI positive cells with treatment of U0126
(p = 0.38) following staining with Hoechst 33342 (Figure S7D). We
subdivided the ABCG2hiSP fraction into cells located at the top of
the tail and cells located at the end of the tail (Figure 5B), as it has
been reported that cells at the tip of the SP tail, which have the
highest Hoechst 33342 efflux capacity (Hoechstlow), highly
enriched the stem cell population [31]. Treatment with the
MEK inhibitor had a marked inhibitory effect on the cells located
in the tail end of the ABCG2hiSP, reducing the ABCG2hiSP by
2.5-fold (5.8% to 2.3%). In contrast, the inhibitor only reduced the
ABCG2hiSP in the non-tail end by 1.5-fold (2.8% to 1.9%). These
data show that U0126 is also exerting its effect on ABCG2hi
Hoechstlow cells. Treatment with U0126 also caused a dose-
dependent inhibition of CFE in RT112 ABCG2hi SP and
ABCG2low NSP cells (Figure S7E). As we have shown that
ABCG2hi SP cells can give rise to both SP and NSP cells (Figure
S7F) and ABCG2low NSP cells have very low levels of pERK, the
suppression of ABCG2low NSP cell CFE appears to be indirect
through the effects of U0126 on ABCG2hi SP cells. Of note,
preferential inhibition of larger colonies, more indicative of CSC
growth, was seen as the presence of colonies $3mm was inhibited
altogether at 1026 M (Figure 5C). These data show that the
ABCG2hi SP fraction is, at least in part, maintained by the
MAPK/ERK pathway which in turn we have shown to maintain
the ABCG2low NSP cells.
Expression of ABCG2 in Clinical Bladder Cancer Correlates
with Grade, Stage, Recurrence and Progression Free
Survival and pERK Expression
To determine the clinical significance of our in vitro and in vivo
cell line findings, we investigated the expression of ABCG2 in
sections of human bladder cancer. Tissue sections from a panel of
148 NMIBC (Table S2– illustrates clinical features) were processed
for immunoreactivity to ABCG2 (Figure 6A). ABCG2 positivity
was detected in 143 (97%) cases, and for comparison a section of
normal urothelium is included which demonstrates a greater
intensity of basal ABCG2 expression, which is in keeping with the
emerging evidence for a basal stem cell [32]. Average immuno-
staining intensity scores for ABCG2 were shown to be associated
with early invasive stage, pTa (n= 87) versus pT1 (n= 61), and
increasing tumour grade, low grade (n= 93) versus high grade
(n= 55) (p,0.05) (Figure 6B). Median follow up was for 59 months
(inter-quartile range = 48.3–96.3 months), and 31 cases (21%)
showed disease recurrence and 23 cases (16%) showed disease
progression. Correlations with time to recurrence and progression
free survival (PFS) revealed worse outcomes associated with
increasing ABCG2 expression as illustrated with Kaplan-Meier
curves and Log-Rank analyses (p,0.001) (Figure 6C). These
correlations remained statistically significant when stratified for
grade, stage and presence of CIS (p,0.001). Using Cox
multivariate analysis, which included the variables of grade, stage
and intensity of ABCG2 immunostaining, revealed that ABCG2
expression remained an independent predictor of disease progres-
sion (p,0.001; RR =5.1; 95%CI = 2.6–9.9). Additionally,
increasing pERK expression was also associated with worse
outcomes (Log-Rank p= 0.001) (Figure 6D). Furthermore, a
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positive correlation was demonstrated between ABCG2 and
pERK expression (p = 0.005, Pearson’s r = 0.99) (Figure 6E).
Discussion
Recent advances in the isolation and characterisation of
putative CSCs have provided exciting insights into the basis of
carcinogenesis and led to increasing optimism for the development
of more effectively targeted cancer therapy. Studies have presented
compelling data demonstrating that a number of human cancers
follow the CSC model, whereby a small subpopulation of cells
within a tumour is capable of tumour initiation and responsible for
tumour growth and recurrence [8,9]. The existence of cells with
increased tumour initiating potential has recently been described
in human bladder cancer [33–35] and SP has been demonstrated
in bladder cancer patient samples [19]. In this study, we
characterised bladder CSCs using SP and explored their
modulation by the MAPK/ERK signalling pathway.
In search of a CSC hierarchy in human bladder cancer, our
in vitro studies showed ABCG2hi SP cells displayed a three-fold
increase in colony forming efficiency. These data were further
supported by our in vivo studies whereby ABCG2hi SP cells were
tumour initiating in comparison to ABCG2low NSP cells which
displayed loss of tumour growth at 16103 cell dilution. These
observations highlight enrichment of CSCs within the ABCG2hi
SP selections. Subsequent serial transplantations would further
support a hierarchical CSC relationship in these tumours.
However, we have taken an analogous approach by performing
serial selections and in vitro cultures of ABCG2hi SP and
ABCG2low NSP cultures demonstrated the ability of ABCG2hi
SP cells to repopulate the original phenotypic spectrum of the
parent RT112 cell line. Serial selections of ABCG2low NSP cells
showed weakening in the potential to regenerate both populations
indicating dilution of the ability to select or generate CSCs.
ABCG2 has been shown to be the main molecular determinant
of the SP phenotype [26]. Indeed, we found the SP of NMIBC
RT112 and RT4 cells had higher ABCG2 mRNA expression, was
completely abrogated by ABCG2-specific inhibitor FTC and
contained the top 5% of ABCG2hi expressing cells. Correlation to
clinical NMIBC outcomes revealed ABCG2hi immunostaining to
be associated with worse clinical outcomes of cancer recurrence
and progression, indicating a role for CSCs in bladder cancer
development. Interestingly, the SP of MIBC J82 cell line had
higher P-glycoprotein expression and was inhibited by verapamil,
a P-glycoprotein-specific inhibitor. P-glycoprotein mRNA levels
have been found to be elevated in high grade bladder tumours
[36]. Additionally, the molecular pathology of NMIBC is distinct
from MIBC [20]. These findings may account for the differences
seen in the % of SP cells in the NMIBC and MIBC cell lines and
suggest a possible switch of CSC phenotype in MIBC.
The existence of CSCs in human bladder cancer has been
reported based on the use of SP, aldehyde dehydrogenase activity
assay, cell surface and cytokeratin markers generally suggesting
basal markers as CSC markers [19,33–35,37,38]. Transcripts of
bladder basal cell markers CK14, CD44, CD49f and CD104 were
all expressed in ABCG2hi SP cells but similar levels of expression
were also seen in ABCG2low NSP cells. Further investigation of
protein expression is required. Of note, we showed protein
expression of ABCG2, the main mediator of SP, is basal consistent
with published data pointing towards basal markers as CSC
markers. Embryonic/pluripotent stem cell-like signatures are
found to be over-expressed in poorly differentiated human
cancers, including bladder cancers [30]. We show that ABCG2hi
SP cells exhibited higher expression levels of Nanog, Notch1 and
SOX2 in comparison to ABCG2low NSP cells. The expression of
these pluripotent stem cell factors may contribute to greater
multipotency in generating SP and NSP from the ABCG2hi SP
cells. Interestingly, increased expression of Nanog in NMIBC
CSCs has also been shown to correlate with overexpression of self-
renewing marker Bmi-1 and a larger population of SP cells [39].
Furthermore, our cell cycle studies showed a greater proportion of
ABCG2hi SP cells were in S-phase in contrast to the G1
positioning of ABCG2low NSP cells, which is consistent with
Nanog, SOX2 and Oct4 in inducing longer S-phase and a shorter
G1 [40,41]. The data presented highlights a potential mechanism
for the ESC-like signatures in promoting tumorigenicity and the
function of these genes in bladder cancer represents an important
area for further study.
Similarly to observations reported in colon cancer cells, we
found inhibition of the MAPK/ERK signalling pathway by
MEK1/2-specific inhibitor U0126 to reduce SP, possibly through
altering ABCG2 expression or localisation [42]. MEK inhibition
has also been shown to down-regulate ABCG2 expression by
promoting its degradation [27] as well as downregulating a
cisplatin-induced SP that is highly tumorigenic and overexpresses
Nanog [43].Additionally, our data showed that inhibition of
MAPK/ERK signalling pathway targeted both bladder CSCs and
non-CSCs as demonstrated by reduced colony forming ability of
ABCG2hi SP and ABCG2low NSP cells. However, the effect of
U0126 on ABCG2low NSP cells appears to be indirect as
ABCG2low NSP cells have very low levels of active ERK but are
hierarchically dependent on ABCG2hi SP cells with high ERK
activity that would be more susceptible to U0126 inhibition. We
show that ABCG2 expression correlated with NMIBC recurrence
and progression, and that ABCG2 expression is, in part, regulated
by MAPK activity and this correlates with ours and published
findings of activated ERK predicting poor prognosis in bladder
cancer [44]. Additionally, we demonstrate ABCG2 expression to
positively correlate with pERK expression. Indeed, the MAPK/
ERK signalling pathway has been distinctively shown to have a
role in CSC self-renewal and tumourigenicity in a number of
cancers [45,46]. Our data therefore goes some way to support the
MAPK pathway being central to maintenance of bladder CSC
phenotype and potentially highlights strategies to usefully modu-
late CSCs; this approach being already a focus of preclinical and
clinical studies for a number of malignancies [47–49]. There are
encouraging results from clinical trials with MEK inhibitors [50],
and our data validates the therapeutic targeting of MEK or its
upstream regulators (e.g. clinical trials of erlotinib) in bladder
cancer [7,51].
In conclusion, we confirm that ABCG2hi SP enriches for CSCs
in human bladder cancer and provide evidence for the importance
of the MAPK pathway as a suitable therapeutic target for NMIBC
CSCs.
Supporting Information
Figure S1 Gating strategy for SP data analysis. An example of
the step-by-step gating strategy and the resulting percentage of cell
populations is shown for RT112. (A) Gating strategy. Cells are
distinguished from debris on the flow cytometric profile based on
Forward Scatter (FSC) and Side Scatter (SSC) (A, 1). The Hoechst
3342 dye is excited with the UV laser at 350 nm and its
fluorescence is measured with a 2-355/450/50 filter (Hoechst
Blue) and a 2-355/675lp filter (Hoechst Red). Doublets and
aggregates are gated out based on Hoechst Blue area versus height
to ensure that a detected signal arises from single cells. PI, having
been excited at 350 nm, is also measured through the 2-355/675lp
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filter but is much brighter than the Hoechst red signal so the dead
cells line up on a vertical line to the far right (A, 2). SP cells are
recognised as a distinct tail extending from the main population
with the characteristic low fluorescent profile based on Hoechst
Red versus Hoechst Blue (A, 3). (B) The gating tree illustrates the
sequential procedure applied to select out the SP population and
the percentage of cells resulting from each gating step. ‘% Parent’
indicates the percentage of gated events relative to the preceding
gate. ‘% Total’ indicates the percentage of gated events relative to
all events recorded.
(TIF)
Figure S2 ABC transporter expression in bladder cancer cell
lines. Real time PCR was used to determine relative expression of
ABC transporter mRNA in bladder cancer cell lines. Expression
levels were normalised to the housekeeping gene GAPDH. Data
shown are the mean of three independent experiments each done
in triplicate (mean 6 SE).
(TIF)
Figure S3 P-glycoprotein transporter mediates SP phenotype in
J82 bladder cancer cells. (A) Real time PCR analysis of ABC
transporter expression in J82 SP and NSP cell. Data shown are the
mean of three independent experiments each done in triplicate
(mean 6 SE). *P,0.05 (Student’s two-tailed t -test). (B) Inhibition
studies were performed on J82 cells using ABCG2-specific
inhibitor fumitremorgin C (FTC) and P-glycoprotein inhibitor
verapamil.
(TIF)
Figure S4 ABCG2 transporter mediates SP phenotype in
RT112 and RT4 bladder cancer cells. Following staining with
Hoechst 33342, cells were labelled with anti-ABCG2-FITC and
normal mouse IgG-FITC was used as isotype control. (A) The 5%
of cells showing the highest intensity immunofluorescence
(population P2 for SP fraction and population P4 for NSP
fraction) were categorised as ABCG2hi population whilst the 5% of
cells showing the lowest intensity of immunofluorescence (popu-
lation P1 for SP fraction and population P3 for NSP fraction) were
categorised as ABCG2low population (representative dot plot). (B)
The gating tree illustrates the sequential procedure applied to
select out the ABCG2hi and ABCG2low populations and the
percentage of cells resulting from each gating step. RT112 (C) and
RT4 (D) cells labelled with anti-ABCG2-FITC and resulting
ABCG2hi and ABCG2low populations for SP and NSP fractions.
These data show that SP cells equate to ABCG2hi expressing cells
and the NSP equate to ABCG2low expressing cells.
(TIF)
Figure S5 RT4 SP cells have a higher clonogenic ability in
comparison to RT4 NSP cells. RT4 FACS sorted cells were
seeded in 6-well plates at a density of 16102 cells/well and
colonies were counted after 2 weeks. Data shown are the mean (6
SE) of three independent experiments each done in triplicate.
*P,0.05 (Student’s two-tailed t-test).
(TIF)
Figure S6 Stem and basal cell marker expression in ABCG2hi
SP and ABCG2low NSP fractions of RT112 cells. Relative mRNA
expression of stem (A) and basal (B) cell markers was determined in
ABCG2hi SP and ABCG2low NSP fractions of RT112 cells using
real time PCR. Data shown are the mean of three independent
experiments each done in triplicate (mean 6 SE). *P,0.05
(Student’s two-tailed t -test).
(TIF)
Figure S7 Inhibition of ERK signalling attenuates the fraction of
ABCG2hi SP RT112 cells. (A) Real time PCR analysis of MAPK
pathway component gene expression was carried out in ABCG2hi
SP and ABCG2low NSP sorted RT112 cells. Data shown are the
mean (6SE) of three independent experiments each done in
triplicate. (B) ABCG2hi SP and ABCG2low NSP xenografts were
stained for pERK. (C) RT112 cells were starved overnight in basal
media (BM) and pretreated with MEK inhibitor U0126 (10mM)
for 30, 60 and 120 mins before being stimulated with recombinant
EGF (r-EGF, 10 and 100 ng/ml) for 5 mins. Western blotting
demonstrating pERK levels. Total ERK levels were used as
loading control. (D) Cell viability using propidium iodide (PI, 2mg/
ml) following staining with Hoechst 33342 in the absence or
presence of U0126 (10mM) (p = 0.38, Student’s two-tailed t-test).
(E) U0126 decreases the CFE of both ABCG2hi SP and ABCG2low
NSP. (F) SP cells sorted from RT112 were cultured for two weeks,
restained with Hoechst 33342 dye and reanalysed by flow
cytometry.
(TIF)
Table S1 Primer sequences for real time PCR.
(DOCX)
Table S2 Characteristics of 148 patients with non muscle
invasive bladder cancer. Table shows number of patients (%)
according to age and sex, in addition to grade and stage stratified
for ABCG2 immunostaining score.
(DOCX)
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